Yan Ming, Meng Fan Li, Lu Rui Juan, Jia Xiao Qing, Zhao Xian Cun
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China.
Zhonghua Gan Zang Bing Za Zhi. 2003 Feb;11(2):86-9.
To investigate the fat decreasing effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats.
Alcoholic fatty liver and drug-induced fatty liver rats models were established. The two kinds of rats with fatty liver were seperatedly divided into fenofibrate treatment group (80 mg/kg daily) and control group without treatment. Rats were killed after four weeks, then the levels of serum triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL) and malondialdehyde (MDA), hepatic lipase (HL), lipoprotein lipase (LPL) both in serum and liver tissue were measured according to the Test Kits. Histopathological changes in liver was dyed with HE and observed under light microscope.
After treatment by fenofibrate, in the serum of rats with alcoholic fatty liver, the level of TG decreased significantly (1.07 mmol/L 0.06 mmol/L vs 1.56 mmol/L 0.29 mmol/L, t=5.115, p<0.001), while the level of TC had no alteration. The levels of MDA both in serum and liver tissue decreased (1.10 nmol/L 0.22 nmol/L vs 1.26 nmol/L 0.21 nmol/L, t=0.592, p<0.05; 5.92 nmol/g 1.24 nmol/g vs 7.42 nmol/g 1.22 nmol/g, t=3.477, p<0.05, respectively), while the levels of HL, LPL in serum and liver tissue increased significantly (Serum: 0.053muEq/ml/h 0.006muEq/ml/h vs 0.037 muEq/ml/h 0.006muEq/ml/h, t=-5.086, p<0.001; 0.018 muEq/ml/h 0.004 muEq/ml/h vs 0.014muEq/ml/h 0.004muEq/ml/h, t=-2.485, p<0.05. Liver tissue: 0.075muEq/ml/h 0.010muEq/ml/h vs 0.065muEq/ml/h 0.007muEq/ml/h, t=-2.437, p<0.05; 0.022 muEq/ml/h 0.014 muEq/ml/h vs 0.008 muEq/ml/h 0.002 muEq/ml/h, t=-2.876, p<0.05). Fat content in liver decreased (26.01 mg/g 1.69 mg/g vs 71.45 mg/g 2.66 mg/g, t=-43.224, p<0.001). The pathological changes of liver in fenofibrate-treated rats with alcoholic fatty liver were improved. For the drug-induced fatty liver rats, fenofibrate treatment group had no difference from the untreated control group.
Fenofibrate can significantly decrease the fat content in liver tissue of rats with alcoholic fatty liver, as well as ameliorating liver pathological changes. But fenofibrate has no effect on drug-induced fatty liver.
探讨非诺贝特对大鼠酒精性脂肪肝和药物性脂肪肝的降脂作用。
建立酒精性脂肪肝和药物性脂肪肝大鼠模型。将两种脂肪肝大鼠分别分为非诺贝特治疗组（每日80mg/kg）和未治疗的对照组。四周后处死大鼠，然后根据试剂盒测定血清甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白（HDL）和丙二醛（MDA）水平，以及血清和肝组织中的肝脂肪酶（HL）、脂蛋白脂肪酶（LPL）。肝组织病理变化用苏木精-伊红染色，在光学显微镜下观察。
非诺贝特治疗后，酒精性脂肪肝大鼠血清中TG水平显著降低（1.07mmol/L±0.06mmol/L vs 1.56mmol/L±0.29mmol/L，t=5.115，p<0.001），而TC水平无变化。血清和肝组织中MDA水平均降低（1.10nmol/L±0.22nmol/L vs 1.26nmol/L±0.21nmol/L，t=0.592，p<0.05；5.92nmol/g±1.24nmol/g vs 7.42nmol/g±1.22nmol/g，t=3.477，p<0.05），而血清和肝组织中HL、LPL水平显著升高（血清：0.053μEq/ml/h±0.006μEq/ml/h vs 0.037μEq/ml/h±0.006μEq/ml/h，t=-5.086，p<0.001；0.018μEq/ml/h±0.004μEq/ml/h vs
